HomeCompareMET vs RS

MET vs RS: Dividend Comparison 2026

MET yields 3.33% · RS yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MET wins by $13.3K in total portfolio value· pulled ahead in Year 2
10 years
MET
MET
● Live price
3.33%
Share price
$68.27
Annual div
$2.27
5Y div CAGR
23%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.3K
Annual income
$4,879.85
Full MET calculator →
RS
RS
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full RS calculator →

Portfolio growth — MET vs RS

📍 MET pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMETRS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MET + RS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MET pays
RS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MET
Annual income on $10K today (after 15% tax)
$282.63/yr
After 10yr DRIP, annual income (after tax)
$4,147.87/yr
RS
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, MET beats the other by $3,383.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MET + RS for your $10,000?

MET: 50%RS: 50%
100% RS50/50100% MET
Portfolio after 10yr
$34.7K
Annual income
$2,889.52/yr
Blended yield
8.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MET right now

MET
Analyst Ratings
24
Buy
8
Hold
Consensus: Buy
Price Target
$96.83
+41.8% upside vs current
Range: $90.00 — $101.00
Altman Z
0.1
Piotroski
8/9
RS
Analyst Ratings
9
Buy
16
Hold
2
Sell
Consensus: Hold
Price Target
$330.00
+560.0% upside vs current
Range: $320.00 — $340.00
Altman Z
6.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MET buys
8
RS buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$MET▼ Sell$1,001 - $15,0002025-08-26
Ro Khanna🏢 House$MET▼ Sell$1,000 - $15,0002025-08-26
Gilbert Cisneros🏢 House$MET▼ Sell$1,001 - $15,0002025-08-06
Ritchie Torres🏢 House$MET▼ Sell$1,001 - $15,0002025-07-11
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002025-06-13
Sheldon Whitehouse🏛 Senate$MET▼ Sell$1,001 - $15,0002024-11-19
Thomas R. Carper🏛 Senate$MET▼ Sell$1,001 - $15,0002024-01-17
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002023-10-31
Sheldon Whitehouse🏛 Senate$MET▼ Sell$1,001 - $15,0002023-09-20
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMETRS
Forward yield3.33%4.00%
Annual dividend / share$2.27$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR23%5%
Portfolio after 10y$41.3K$28.0K
Annual income after 10y$4,879.85$899.19
Total dividends collected$18.1K$6.4K
Payment frequencyquarterlyquarterly
SectorFinancialsMaterials
Analyst consensusBuyHold
Analyst price target$96.83$330.00

Year-by-year: MET vs RS ($10,000, DRIP)

YearMET PortfolioMET Income/yrRS PortfolioRS Income/yrGap
1$11,109$408.98$11,120$420.00$11.00RS
2← crossover$12,409$522.27$12,357$458.31+$52.00MET
3$13,948$670.62$13,721$499.76+$227.00MET
4$15,791$866.52$15,227$544.58+$564.00MET
5$18,024$1,127.71$16,885$593.02+$1.1KMET
6$20,765$1,479.66$18,713$645.34+$2.1KMET
7$24,179$1,959.61$20,724$701.81+$3.5KMET
8$28,494$2,622.90$22,938$762.73+$5.6KMET
9$34,042$3,553.25$25,372$828.41+$8.7KMET
10$41,305$4,879.85$28,047$899.19+$13.3KMET

MET vs RS: Complete Analysis 2026

METFinancials

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.

Full MET Calculator →

RSMaterials

RS is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in RS shares.

Full RS Calculator →
📬

Get this MET vs RS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MET vs SCHDMET vs JEPIMET vs OMET vs KOMET vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.